指南与共识骨质疏松与代谢性骨病

日本实施糖皮质激素性骨质疏松症治疗指南的成本效果分析

Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan.
指南 / 共识 · Osteoporos Int · 2019-01-04

本研究基于患者水平状态转移模型,评估日本绝经后骨量减少或骨质疏松女性使用糖皮质激素时,按指南指征接受5年阿仑膦酸钠治疗的成本效果。结果显示,在当前日本临床指南指征下,除少数骨折低风险患者外,该治疗可能具有成本效果。

要点

  • 55岁、骨密度为年轻成人均值75%的用药女性,ICER为每QALY 10,958至29,727美元。
  • 年龄越低、骨密度越低、糖皮质激素剂量越高、有既往骨折者,ICER越低。
  • 最佳情形(45岁、70%YAM、10mg/日、有既往骨折)可节省医疗成本。

核心结论

  • 预防性阿仑膦酸钠治疗对使用糖皮质激素的绝经后骨量减少或骨质疏松女性的成本效果对年龄、骨密度、糖皮质激素剂量和既往骨折存在敏感性。
  • 分析提示,当前日本临床指南中该类人群的治疗指征可能具有成本效果,但骨折低风险患者除外。

研究设计与样本

  • 研究采用患者水平状态转移模型,预测使用糖皮质激素的绝经后日本骨量减少或骨质疏松女性的终身成本和QALYs。
  • 成本和QALYs均采用每年2%的贴现率。
  • 比较5年阿仑膦酸钠治疗与不治疗的ICER,并组合起始年龄(45、55或65岁)、股骨颈骨密度(YAM的70%、75%或80%)、糖皮质激素剂量(每日2.5、5或10 mg)和既往骨折(有或无)等风险因素。

主要发现

  • 55岁、骨密度为YAM 75%的使用糖皮质激素女性,ICER范围为每QALY 10,958至29,727美元。
  • 情景分析显示,年龄越低、骨密度越低、糖皮质激素剂量越高、有既往骨折与更低的ICER相关。
  • 最佳情景为45岁、骨密度70%YAM、糖皮质激素每日10 mg且有既往骨折,结果为节省医疗成本。
  • 最差情景为65岁、骨密度80%YAM、糖皮质激素每日2.5 mg且无既往骨折,ICER为每QALY 66,791美元。
  • 最差情景的敏感性分析显示,成本和健康获益的年贴现率对估计的ICER有强影响;其他参数如椎体骨折所致失能效用、阿仑膦酸钠疗效等也影响ICER,但ICER仍超过每QALY 50,000美元。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: A model-based cost-effectiveness analysis was performed to evaluate the cost-effectiveness of implementing the clinical guideline for the treatment for glucocorticoid-induced osteoporosis (GIO). The treatment indication for GIO in the current Japanese clinical guidelines is likely to be cost-effective except for the limited patients who are at low risk for fracture. INTRODUCTION: The purpose of this study was to evaluate the cost-effectiveness of implementing the clinical guideline for the treatment for glucocorticoid-induced osteoporosis (GIO) from the perspective of the Japanese healthcare system. METHODS: A patient-level state transition model was developed to predict lifetime costs and quality-adjusted life years (QALYs) in postmenopausal Japanese women with osteopenia or osteoporosis using glucocorticoid (GC). An annual discount rate of 2% for both costs and QALYs was applied. The incremental cost-effectiveness ratio (ICER) of 5-year alendronate therapy compared with no therapy was estimated with different combinations of the risk factors such as starting age (45, 55, or 65), femoral neck BMD (% young adult mean (YAM) of 70%, 75%, or 80%), dose of GC (2.5, 5, or 10 mg per day), and the presence of previous fracture (yes or no). RESULTS: For 55-year-old women using GC with a BMD of 75% of YAM, the ICER ranged from $10,958 to $ 29,727 per QALY. Scenario analyses indicated that the lower age, the lower BMD, the higher dose of GC, and the presence of previous fracture associated with lower ICER. The best-case scenario was 45-year-old women with a BMD of 70% of YAM, GC dose of 10 mg per day, and previous fracture, and resulted in healthcare cost-savings. The worst-case scenario was 65-year-old women with a BMD of 80% of YAM, GC dose of 2.5 mg per day, and no previous fracture, and resulted in the ICER of $66,791 per QALY. Sensitivity analyses in the worst-case scenario showed that the annual discount rate for costs and health benefit had the strong influence on the estimated ICER. Although the ICER was influenced by other parameters such as disutility due to vertebral fracture, efficacy of alendronate, and so on, the ICERs remained more than $50,000 per QALY. CONCLUSIONS: The cost-effectiveness of preventive alendronate therapy for postmenopausal women with osteopenia or osteoporosis using GC is sensitive to age, BMD, GC dose, and the presence of previous fracture. Our analysis suggested that the treatment indication for postmenopausal women with osteopenia or osteoporosis using GC in the current Japanese clinical guidelines is likely to be cost-effective except for the limited patients who are at low risk for fracture.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Moriwaki K, Fukuda H. Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan. Osteoporos Int. 2019. PMID: 30610244. doi:10.1007/s00198-018-4798-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。